25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Publication number: 20140255349Abstract: The invention relates to peptides and functional derivatives thereof and their use for improving transduction efficiency of viruses into target cells.Type: ApplicationFiled: June 28, 2012Publication date: September 11, 2014Applicants: GENETHON, Institut National de la Sainte et de la recherche Madicale, Centre National de la Recherche ScientiqueInventors: David Fenard, Antoine Kichler, Samia Martin
-
Publication number: 20140256614Abstract: Compositions and methods for activating MK2, augmenting permeability barriers, such as epithelial and/or endothelial barriers, and treating diseases, conditions, disorders, and/or injuries associated therewith, such as pulmonary edema and other lung diseases and injuries are provided herein.Type: ApplicationFiled: August 16, 2012Publication date: September 11, 2014Applicant: TUFTS MEDICAL CENTERInventor: Usamah S. Kayyali
-
Publication number: 20140256912Abstract: Internally cross-linked peptides derived from human MAML and derivatives thereof which exhibit affinity for the ICN1-CSL complex are described and characterized. The peptides can interfere with NOTCH signaling and are thus useful for treating various disorders, including certain cancers.Type: ApplicationFiled: June 15, 2012Publication date: September 11, 2014Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Raymond Earle Moellering, Gregory L. Verdine
-
Publication number: 20140256879Abstract: Method for assembling proteins from peptide fragments. It allows the production of proteins in a manner that is simple, reliable and applicable on an industrial scale. This method allows the production of proteins of therapeutic or diagnostic interest. Kits for applying this synthesis method as well as test and/or diagnostic kits are also described.Type: ApplicationFiled: October 16, 2012Publication date: September 11, 2014Inventors: Oleg Melnyk, Laurent Raibaut, Vincent Aucagne, Agnes Delmas
-
Publication number: 20140256626Abstract: Slow release forms of exenatide wherein exenatide is releasably linked to polyethylene glycol carriers are disclosed.Type: ApplicationFiled: October 17, 2012Publication date: September 11, 2014Inventors: Daniel V. Santi, Eric L. Schneider, Gary W. Ashley
-
Publication number: 20140255513Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.Type: ApplicationFiled: September 26, 2013Publication date: September 11, 2014Inventors: Carola Leuschner, Hector Alila
-
Publication number: 20140255416Abstract: Disclosed are polypeptides for Campylobacter jejuni that are useful as immungenic agents for vaccine use. Also disclosed are nucleic acid fragments encoding the polypeptides as well as compositions, methods and molecular biology tools derived from or related to the proteins.Type: ApplicationFiled: October 12, 2012Publication date: September 11, 2014Inventors: Niels Iversen Møller, Andreas Mattsson
-
Publication number: 20140256630Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.Type: ApplicationFiled: January 7, 2014Publication date: September 11, 2014Applicant: Indi Molecular, Inc.Inventors: Suresh Mark PITRAM, Heather Dawn AGNEW, Tsun Yin LAI, Rosemary Dyane ROHDE, Paul Edward Kearney, Scott LAW, Kenneth Charles FANG
-
Publication number: 20140248603Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.Type: ApplicationFiled: February 28, 2014Publication date: September 4, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Marc Allan EICHMEYER, Michael B. ROOF, Merrill Lynn SCHAEFFER, Eric Martin VAUGHN, Kun YANG, Jeremy Richard RUSH, Daniel John MURFIN
-
Publication number: 20140248631Abstract: The present invention relates a method for the diagnosis, prediction or risk stratification for mortality and/or disease outcome of a subject that has or is suspected to have sepsis, comprising determining the presence and/or level of antitrypsin (ATT) or fragments thereof in a sample taken from said subject and/or determining the presence and/or level of transthyretin (TTR) or fragments thereof, wherein the presence and/or level of ATT and/or TTR or fragments thereof is correlated with an increased risk of mortality and, wherein said increased risk of mortality and/or poor disease outcome is given if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value and/or said increased risk of mortality and/or poor disease outcome is given if the level of TTR is below a certain cut-off value and/or the level of fragments thereof is below a certain cut-off value.Type: ApplicationFiled: November 14, 2012Publication date: September 4, 2014Inventors: Michael Kiehntopf, Diana Schmerler, Thomas Deufel, Frank Brunkhorst
-
Publication number: 20140249090Abstract: The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide S receptor (NPSR), of the receptor TGR23 and/or of vasopressin receptor-related receptor 1 (VRR1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nType: ApplicationFiled: April 2, 2012Publication date: September 4, 2014Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFT E.V.Inventors: Yi-Chun Yen, Axel Steiger, Florian Holsboer, Rainer Landgraf, Irina Alexandra Ionescu, Ulrike Schmidt
-
Publication number: 20140249052Abstract: The present invention provides polypeptides that bind to inorganic solid surfaces, structures comprising such polypeptides, and methods of making such structures.Type: ApplicationFiled: October 24, 2012Publication date: September 4, 2014Inventors: Sarikaya Mehmet, Yuhei Hayamizu, Christopher R. So, Candan Tamerler-Behar
-
Publication number: 20140248272Abstract: The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in Treponema spp. isolated from digital dermatitis in cattle. The present invention further relates to antibodies raised against said proteins or fragments thereof, and the use of said proteins in diagnostic methods in which antibodies are detected as a sign of digital dermatitis in cattle.Type: ApplicationFiled: March 4, 2014Publication date: September 4, 2014Inventors: Anna ROSANDER, Märit PRINGLE
-
Publication number: 20140249089Abstract: The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.Type: ApplicationFiled: January 31, 2014Publication date: September 4, 2014Applicant: ARES TRADING SAInventors: James Rasmussen, Jianxin Zhang, Sam Baldwin, Eric Zannelli, Bei Yu, Dustan Bonnin, Keith Johnson, Jeff Krieger
-
Patent number: 8822409Abstract: Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.Type: GrantFiled: June 20, 2008Date of Patent: September 2, 2014Assignee: Phylogica LimitedInventors: Nadia Marian Dorothy Milech, Paul Michael Watt, Patrick G. Holt, Deborah Strickland
-
Patent number: 8822413Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).Type: GrantFiled: July 7, 2008Date of Patent: September 2, 2014Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Patent number: 8821894Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.Type: GrantFiled: July 1, 2011Date of Patent: September 2, 2014Assignee: The University of ChicagoInventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim
-
Patent number: 8822417Abstract: Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.Type: GrantFiled: May 4, 2012Date of Patent: September 2, 2014Assignee: Novozymes Biopharma DIC A/SInventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Publication number: 20140243272Abstract: An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man.Type: ApplicationFiled: May 16, 2014Publication date: August 28, 2014Applicant: ALPHABETA ABInventor: Jan Johansson
-
Publication number: 20140243268Abstract: Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length.Type: ApplicationFiled: February 24, 2014Publication date: August 28, 2014Applicant: Georgia Regents Research Institute, Inc.Inventors: Lin Mei, Wen-Cheng Xiong, Cheng-Yong Shen, Yan-Mei Tao, Shi-Wen Luo
-
Publication number: 20140243256Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).Type: ApplicationFiled: March 14, 2013Publication date: August 28, 2014Applicant: The Administrators of the Tulane Educational FundInventors: Jennifer S. SPENCE, Robert F. GARRY
-
Publication number: 20140239237Abstract: Electrically conductive nanowires, and genetically or chemically modified production and use of such nanowires with altered conductive, adhesive, coupling or other properties are described. The disclosed nanowires are used as device or device components or may be adapted for soluble metal remediation.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITYInventors: Gemma REGUERA, Dena COLOGGI, Robert Mark WORDEN, Angelines A. CASTRO-FORERO, Rebecca STEIDL
-
Patent number: 8815803Abstract: This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention provides: a composition for increasing the body height of an individual comprising a guanyl cyclase B (GC-B) activator as an active ingredient, the composition being to be administered to an individual free from FGFR3 abnormality; a method for increasing the body height of an individual free from FGFR3 abnormality which comprises activating GC-B; a method for screening an agent for increasing the body height of an individual which comprises selecting an agent for increasing the body height using GC-B activity as an indication; and a method for extending a cartilage bone free from FGFR3 abnormality which comprises activating GC-B in an individual.Type: GrantFiled: March 31, 2005Date of Patent: August 26, 2014Inventors: Kazuwa Nakao, Akihiro Yasoda, Hidetomo Kitamura
-
Patent number: 8815811Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.Type: GrantFiled: March 23, 2011Date of Patent: August 26, 2014Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Krister Bengt Bokvist, Lili Guo, John Philip Mayer
-
Patent number: 8815812Abstract: The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumors, pain, wounds and/or scars.Type: GrantFiled: April 19, 2011Date of Patent: August 26, 2014Assignee: Inger Mattsby-BaltzerInventors: Inger Mattsby-Baltzer, Gunnar Dolphin
-
Publication number: 20140235549Abstract: The present invention provides inventive polypeptides comprising a C terminal RAB binding domain (RabBD) of RAB family interacting proteins (FIPs) stabilized by peptide stapling, and pharmaceutical compositions thereof. Also provided are methods for modulating RAB function comprising contacting an inventive stapled polypeptide with a RAB protein, and methods of treatment associated with modulation of RAB activity. The present invention also provides methods of making the inventive stapled polypeptides by ring closing metathesis of unstapled polypeptide precursors.Type: ApplicationFiled: June 15, 2012Publication date: August 21, 2014Applicant: President and Fellows of Harvard CollegeInventors: Raymond E. Moellering, Gregory L. Verdine
-
Publication number: 20140234862Abstract: Provided herein are fluorescent lipid binding proteins (FLBPs). The FLBPs comprise a lipid binding domain linked to a fluorophore, whereby the fluorophore's fluorescence emission undergoes a spectral change upon lipid binding.Type: ApplicationFiled: February 10, 2014Publication date: August 21, 2014Applicant: The Board of Trustees of the University of IllinoisInventor: Wonhwa Cho
-
Publication number: 20140235538Abstract: The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.Type: ApplicationFiled: January 15, 2014Publication date: August 21, 2014Applicant: NOVARTIS AGInventors: David Jonathan GLASS, Mara FORNARO
-
Publication number: 20140234221Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.Type: ApplicationFiled: April 2, 2014Publication date: August 21, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Hongtao Zhang, Xiaomin song, Ramachandran Murali, Masahide Tone
-
Publication number: 20140234868Abstract: The present invention relates to glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand acting on LPA1 (lysophosphatidic acid; 1- or 2-acyl-sn-glycerol-3-phosphate), LPA2, LPA3, LPA4 and LPA5 receptors whose efficacy is exhibited physiologically/pharmaceutically via an interaction with subset receptors [LPA1(edg-2), LPA2(edg-4), LPA3(edg-7), LPA4, PLA5] in the EDG (endothelial differentiation gene) family in G protein-coupled receptors (GPCRs) present in the cell membranes of animals including humans.Type: ApplicationFiled: September 19, 2012Publication date: August 21, 2014Applicant: KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.Inventors: Seung Yeol Nah, Sung Hee Hwang, Tae Joon Shin, Sun Hye Choi
-
Publication number: 20140235789Abstract: The present application discloses peptides and peptaibols of high purity may be obtained by solid phase peptide synthesis using as the starting resin hydroxy amino acids, hydroxy amino acid amides, hydroxy amino alcohols or small peptides containing hydroxy amino acids attached to polymers through their side chain.Type: ApplicationFiled: February 21, 2013Publication date: August 21, 2014Applicant: Chemical & Biopharmaceutical Laboratories of Patras S.A.Inventor: Chemical & Biopharmaceutical Laboratories of Patras S.A.
-
Publication number: 20140234356Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.Type: ApplicationFiled: December 23, 2013Publication date: August 21, 2014Applicant: IMMUNE TARGETING SYSTEMS LTD.Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Victor Gilbert Georges, Philip J. Sizer
-
Publication number: 20140234903Abstract: A novel gene cluster encoding polypeptides involved in the generation of bio synthetically unique peptide-based compounds is described. In addition, new methods for biosynthetic engineering and production of modified peptides and proteins are disclosed. Furthermore, new tools for identification of homologue polypeptides and precursor peptides in other species are provided. In addition, peptide-based compounds and fusions of these compounds with functional moieties for treatment of disorders such as tumors are disclosed.Type: ApplicationFiled: September 5, 2012Publication date: August 21, 2014Applicant: ETH ZURICHInventors: Jorn Piel, Cristian Gurgui, Michael Francis Freeman, Agustinus Robert Uria, Maximilian Johannes Helf
-
Patent number: 8808666Abstract: The present invention provides a novel method of detecting amyloids in a subject. The present invention provides peptides that bind selectively to amyloids and are useful for detecting amyloids and diagnosing and/or monitoring the progression of amyloid mediated conditions.Type: GrantFiled: September 26, 2012Date of Patent: August 19, 2014Assignee: University of Tennessee Research FoundationInventors: Jonathan Wall, Stephen J. Kennel
-
Patent number: 8809494Abstract: Isolated proteins and nucleic acid sequence encoding such protein that interacts with a red blood cell to be invaded by a malaria parasite and link with a component of the actin-myosin based machinery of the malaria parasite are provided. In addition methods for identifying agents which inhibit the function of these proteins as chemotherapeutic and/or immunologic agents for treatment and prevention of malaria infections are provided. Compositions for treatment and prevention of malaria infections and methods for preventing and treating malaria infections are also provided.Type: GrantFiled: November 17, 2005Date of Patent: August 19, 2014Assignee: Drexel UniversityInventors: Lawrence W. Bergman, Akhil B. Vaidya
-
Patent number: 8809002Abstract: The disclosure features a variety of compositions and methods for modulating an interaction between MUC1 and caspase-8 and/or an interaction between MUC1 and a DED-containing protein (e.g., an anti-apoptotic DED-containing protein or a pro-apoptotic DED-containing protein). Such methods and compositions are useful for the treatment or prevention of e.g., a variety of pathological disorders characterized by elevated or decreased levels of apoptosis. Moreover, the compositions and methods are also useful to identify, design, and generate compounds that modulate the interactions. The compounds and/or pharmaceutical compositions containing the compounds can be used in the treatment of disease.Type: GrantFiled: July 9, 2009Date of Patent: August 19, 2014Assignee: Dana-Farber Cancer Institute, Inc.Inventor: Donald W. Kufe
-
Patent number: 8809262Abstract: The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.Type: GrantFiled: April 21, 2009Date of Patent: August 19, 2014Assignees: Singapore Health Service Pte Ltd., Agency for Science, Technology and ResearchInventors: Roger W. Beuerman, Shouping Liu, Jing Li, Lei Zhou, Chandra Shekhar Verma, Donald Tan
-
Patent number: 8809497Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.Type: GrantFiled: December 18, 2008Date of Patent: August 19, 2014Assignee: Annexin Pharmaceuticals ABInventors: Johan Frostegard, Knut Pettersson
-
Publication number: 20140227767Abstract: The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein. In some aspects, the method can be used in the diagnosis, prevention, or treatment of a disease, such as an infection, cancer, autoimmune disease, or inflammatory disease.Type: ApplicationFiled: May 1, 2013Publication date: August 14, 2014Inventors: Michael R. YEAMAN, Nannette Y. YOUNT, Eric P. BRASS
-
Publication number: 20140228298Abstract: Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.Type: ApplicationFiled: February 4, 2014Publication date: August 14, 2014Applicant: Henry Ford Health SystemsInventors: John Anagli, Donald Seyfried
-
Publication number: 20140228540Abstract: The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.Type: ApplicationFiled: April 22, 2014Publication date: August 14, 2014Applicant: Amgen Inc.Inventors: Roy A. Black, Peng Li, Joshua Silverman
-
Publication number: 20140230083Abstract: The present invention concerns new modular base-per-base specific nucleic acid binding domains (MBBBD) derived from newly identified proteins from the bacterial endosymbiont Burkholderia Rhizoxinica and their use for engineering nucleic acid processing enzymes, such as specific endonucleases or transcription activators.Type: ApplicationFiled: July 24, 2013Publication date: August 14, 2014Applicant: CELLECTISInventors: Claudia Bertonati, Philippe Duchateau, Alexandre Juillerat, George Silva, Julien Valton
-
Publication number: 20140228293Abstract: The present invention provides parathyroid hormone and/or parathyroid hormone-related protein analogs, compositions thereof and methods thereto.Type: ApplicationFiled: March 1, 2012Publication date: August 14, 2014Applicants: THE GENERAL HOSPITAL CORPORATION, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Shiying Shang, Zhongping Tan, Suwei Dong, Jianfeng Li, Thomas Gardella
-
Publication number: 20140227311Abstract: The present invention concerns a method for removal of immunosuppressive effects of envelope glycoproteins derived from human immunodeficiency virus, such as for vaccination purposes and for generation of neutralizing antibodies to HIV. The invention further concerns vaccines and antibodies obtainable by the method, as well as the use of such vaccines and antibodies.Type: ApplicationFiled: August 15, 2012Publication date: August 14, 2014Applicant: SKAU APSInventors: Shervin Bahrami, Mogens Ryttergaard Duch
-
Publication number: 20140227313Abstract: Immunogenic group A streptococcus M-related polypeptides and peptides and immunogenic compositions comprising these M-related polypeptides and peptides are provided herein that evoke cross-opsonic and cross-protective anti-GAS and anti-SDSE antibodies in animals. Also provided are preparations comprising immunogenic compositions that comprise M-related polypeptides, peptides, or fusion proteins and that further comprise at least one additional group A streptococcus immunogen, such as an M peptide or Spa peptide.Type: ApplicationFiled: February 11, 2014Publication date: August 14, 2014Inventors: James B. Dale, Harry S. Courtney
-
Publication number: 20140227279Abstract: Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.Type: ApplicationFiled: August 9, 2012Publication date: August 14, 2014Applicant: Lankenau Institute for Medical ResearchInventors: Lisa Laury-Kleintop, Laura Mandik-Nayak, George C. Prendergast, James Duhadaway
-
Patent number: 8802634Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: GrantFiled: July 13, 2009Date of Patent: August 12, 2014Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 8802631Abstract: The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of STM/Hop to PrPc. The invention is directed to methods for treating cancer which rely on interfering with the Hop-PrPc interaction and to peptides, and antibodies raised against the peptides, which directly provide that interference. The invention is further based on the discovery that STI1230-245 peptide and its human homologue Hop23o-245 provide the desired interference with the STI1/Hop-PrPc interaction and inhibit the STI 1/Hop-induced proliferation of glioma and glioblastoma cells. The invention is thus further directed to methods of treating cancer that employ these peptides and functional derivatives thereof, and antibodies directed to the peptides and derivatives. The invention is further directed to means of treating cancer which involve reducing the effective amount of Hop or reducing the expression of Hop.Type: GrantFiled: September 17, 2008Date of Patent: August 12, 2014Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Rafael Bierig Erlich, Luciana Chiarini, Vilma R. Martins, Rafael Linden, Vivaldo Moura Neto
-
Publication number: 20140221608Abstract: An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula PEP1-L-PEP2. The inventive linker, L, is described in various embodiments, each of which provides substantially more rapid acid-release of peptides of interest than does a single aspartic acid-proline pair. In an additional aspect, a method of increasing the stability of an acid cleavable linkage to acid hydrolysis is also provided.Type: ApplicationFiled: April 15, 2014Publication date: August 7, 2014Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: LAURA A BEDZYK, Stephen R. Fahnestock, Tanja Maria Gruber, Daniel P. O'Keefe, Pierre E Rouviere